...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>British Journal of Haematology >Outcome disparities in multiple myeloma: A SEER-based comparative analysis of ethnic subgroups
【24h】

Outcome disparities in multiple myeloma: A SEER-based comparative analysis of ethnic subgroups

机译：多发性骨髓瘤的结果差异：基于SEER的种族亚组比较分析

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Studies of ethnic disparities in malignancies have revealed variation in clinical outcomes. In multiple myeloma (MM), previous literature has focused only on patients of Caucasian and African-American (AA) descent. We present a Surveillance Epidemiology and End Results (SEER)-based outcome analysis of MM patients from a broader range of ethnicities, representing current United States demographics. The SEER 17 Registry data was utilized to analyse adult MM patients diagnosed since 1992 (n = 37 963), as patients of other ethnicities were not well represented prior to that. Overall survival (OS) and myeloma-specific survival (MSS) were compared across different ethnicities stratified by year of diagnosis, registry identification, age, sex and marital-status. Hispanics had the youngest median age at diagnosis (65 years) and Whites had the oldest (71 years) (P < 0·001). Increased age at diagnosis was an independent predictor of decreased OS and MSS. Asians had the best median OS (2·7 years) and MSS (4·1 years), while Hispanics had the worst median OS (2·4 years). These trends were more pronounced in patients ≥75 years. Cumulative survival benefit over successive years was largest among Whites (1·3 years) and smallest among Asians (0·5 years). These disparities may be secondary to multifactorial causes that need to be explored and should be considered for optimal triaging of healthcare resources.
机译：对恶性肿瘤中种族差异的研究表明，临床结果存在差异。在多发性骨髓瘤（MM）中，以前的文献仅集中于白种人和非裔（AA）血统的患者。我们提出了一种基于监测流行病学和最终结果（SEER）的来自更广泛种族的MM患者的结局分析，代表了当前的美国人口统计数据。 SEER 17 Registry数据用于分析自1992年以来诊断的成年MM患者（n = 37 963），因为在此之前其他种族的患者没有得到很好的代表。比较了按诊断年份，登记身份，年龄，性别和婚姻状况分层的不同种族的总生存期（OS）和骨髓瘤特异性生存期（MSS）。西班牙裔美国人的诊断中位数年龄最小（65岁），而白人最大（71岁）（P <0·001）。诊断时年龄的增加是OS和MSS降低的独立预测因素。亚洲人的OS中位数最佳（2·7年）和MSS（4·1年），而西班牙裔的OS中位数最低（2·4年）。这些趋势在≥75岁的患者中更为明显。连续几年的累积生存收益在白人中最大（1·3年），在亚洲人中最小（0·5年）。这些差异可能是多因素原因的继发因素，需要对其进行探讨，并应考虑将这些因素用于医疗资源的最佳分类。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号